Table 2 Study characteristics in Multibacillary Leprosy
Study | Study Design | Country | Follow Up (years) | N | Age (Years) | Diagnosis | Control Used | Evaluated Outcome |
|---|---|---|---|---|---|---|---|---|
Balagon 2011 [28] | Cohort | Philippines | 2 | 589 | 6–73 | NR | MDT 2y | Type II reaction |
Bathki, 1992 [29] | RCT | India | 2 | 16 | NR | Clinical and smear | MDT + vaccine | BI |
Fajardo, 2009 [30] | RCT | Philippines | 12 | 1483 | 15–64 | Clinical and smear | -MDT 1y - 1 month of daily RFP + ofloxacin -MDT 1y + 1-month daily RFP/ofloxacin | -Relapse -Skin smear |
Fernandes Pena 2012 [31] | RCT | Brazil | 4.9 | 613 | Mean 40.15 | NR | Monthly RFP, dapsone and clofazimine daily × 6 m | Type I or II or pure neuritis |
Gunawan, 2018 [32] | RCT | Indonesia | 0.25 | 14 | 41. 71±12.53 | BI and smear | clarithromycin+ dapsone+ clofazimine | BI |
Jadhav, 1992 [33] | RCT | India | 2 | 88 | Mean 24 | Smear | RFP daily for 9 months and then 1 month till the end of 2 years + dapsone + clofazimine daily | -BI -Morphological index |
Maghanoy, 2018 [34] | RCT | Philippines | 2 | 100 | Median 30 | NR | MDT + 12 months of clofazimine | Type II reaction |
Oliveira Penna. 2017 [35] | RCT | Brazil | 5 | 613 | Mean 40.2 | NR | RFP + dapsone + clofazimine × 6 m | -BI -Type I and II reactions -Disability -Relapse rate |
Rao 2009 [27] | Not randomized | India | 2 | 32 | NR | Clinical | RFP + dapsone + clofazimine × 6 m | Clinical and histopathological score |
Sampoonachot, 1997 [36] | RCT | Thailand | 6 | 60 | 12–75 | NR | -MDT + ofloxacin. - ofloxacin + clofazimine, then MDT | -BI -Histological improvement |
Shaw, 2003 [37] | Not randomized | India | 2 | 44 | 37.2 ± 14.3 | NR | RFP + clofazimine+ acedapsone + dapsone | BI |
Souza Cunha 2012 [38] | RCT | Brazil | 7 after the end of tx | 198 | NR | Untreated MB with BI ≧ 2 | -MDT 1y + 1 m of ofloxacin -MDT 1y + 1 m of daily ofloxacin -MDT 1y + daily RFP | Relapse |
Tejasvi, 2006 [39] | RCT | India | 1 | 30 | 27.67 ± 13.08 31.50 ± 17.03 | NR | RFP+ sparfloxacin + clarithromycin + minocycline | -BI -Morphological index -Histopathology -Clinical evaluation |
Villahermosa, 2004 [40] | RCT | Philippines | 2. Additional 8y | 21 | 16–59 | Clinical and smear (> 1 of 6 smear sites having a BI ≧ 1) | ROM (24 consecutive monthly observed doses of rifampin (600 mg), ofloxacin (400 mg), and minocycline (100 mg). | Lesion resolution |